Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Unity Biotechnology expects cash, cash equivalents to fund operations into 2H21 » 08:09
07/31/20
07/31
08:09
07/31/20
08:09
UBX

Unity Biotechnology

$9.54 /

+0.31 (+3.36%)

UNITY believes that…

UNITY believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the second half of 2021.

ShowHide Related Items >><<
UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

07/28/20
Fly Intel: Top five analyst initiations
07/27/20 Roth Capital
Unity Biotechnology initiated with a Buy at Roth Capital
12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

Hot Stocks
Unity Biotechnology to initiate Phase 1 safety study for UBX1325 in 2H20 » 08:09
07/31/20
07/31
08:09
07/31/20
08:09
UBX

Unity Biotechnology

$9.54 /

+0.31 (+3.36%)

In July 2020, UNITY…

In July 2020, UNITY announced that it has completed Investigational New Drug application -enabling studies with UBX1325, an investigational senolytic, small molecule inhibitor of the anti-apoptotic Bcl-2 family member, Bcl-xL. Assuming clinical sites are able to recruit and retain investigators and study staff and screen and enroll patients during the ongoing COVID-19 pandemic, UNITY expects to initiate a Phase 1 safety study for UBX1325 in the second half of 2020 and obtain initial results from the study in 2021. The overall clinical program is directed at multiple age-related diseases of the eye, such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration.

ShowHide Related Items >><<
UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

07/28/20
Fly Intel: Top five analyst initiations
07/27/20 Roth Capital
Unity Biotechnology initiated with a Buy at Roth Capital
12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

Hot Stocks
Unity Biotechnology expects 12-week results from Phase 2 UBX0101 study in Q3 » 08:08
07/31/20
07/31
08:08
07/31/20
08:08
UBX

Unity Biotechnology

$9.54 /

+0.31 (+3.36%)

In July 2020, UNITY…

In July 2020, UNITY announced that it expects to announce topline 12-week results from its Phase 2 study of UBX0101 in the third quarter of 2020. Consistent with prior guidance, 24-week results are also expected by the end of 2020. The company previously announced completion of enrollment of a Phase 2 study of UBX0101 in patients with moderate-to-severe osteoarthritis of the knee in February 2020. The study is randomized, double-blind, and placebo-controlled and will evaluate three doses of UBX0101 administered via a single intra-articular injection. UNITY is also conducting a Phase 1b study of UBX0101 in patients with moderate-to-severe OA of the knee. Enrollment in this study was completed in March 2020. The study is randomized, double-blind, and placebo-controlled and will explore the safety, tolerability and initial efficacy of a single 8.0 mg dose or multiple doses of UBX0101. Consistent with prior guidance, both 12- and 24-week results are expected in the second half of 2020.

ShowHide Related Items >><<
UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

07/28/20
Fly Intel: Top five analyst initiations
07/27/20 Roth Capital
Unity Biotechnology initiated with a Buy at Roth Capital
12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

Earnings
Unity Biotechnology reports Q2 EPS (38c), consensus (51c) » 08:07
07/31/20
07/31
08:07
07/31/20
08:07
UBX

Unity Biotechnology

$9.54 /

+0.31 (+3.36%)

"We are pleased with…

"We are pleased with the progress we are making on advancing programs that target senescent cells to alter the course of diseases of aging," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "The second half of 2020 is a very important period for UNITY, with our topline 12-week Phase 2 data readout from the UBX0101 program in osteoarthritis expected in the third quarter, as well as the commencement of our initial clinical program in ophthalmology later in the second half of the year."

ShowHide Related Items >><<
UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

07/28/20
Fly Intel: Top five analyst initiations
07/27/20 Roth Capital
Unity Biotechnology initiated with a Buy at Roth Capital
12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
UBX Unity Biotechnology
$9.54 /

+0.31 (+3.36%)

Over a week ago
Initiation
Fly Intel: Top five analyst initiations » 10:06
07/28/20
07/28
10:06
07/28/20
10:06
BMY

Bristol-Myers

$58.69 /

+0.64 (+1.10%)

, BYND

Beyond Meat

$127.45 /

+0.71 (+0.56%)

, SAIA

Saia

$128.91 /

-0.26 (-0.20%)

, PODD

Insulet

$191.49 /

-1.03 (-0.54%)

, UBX

Unity Biotechnology

$9.36 /

+0.58 (+6.61%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Bristol-Myers (BMY) initiated with an Outperform at Raymond James. 2. Beyond Meat (BYND) initiated with a Hold at Canaccord. 3. Saia (SAIA) initiated with a Neutral at BofA. 4. Insulet (PODD) initiated with an Overweight at Wells Fargo. 5. Unity Biotechnology (UBX) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
UBX Unity Biotechnology
$9.36 /

+0.58 (+6.61%)

SAIA Saia
$128.91 /

-0.26 (-0.20%)

PODD Insulet
$191.49 /

-1.03 (-0.54%)

BYND Beyond Meat
$127.45 /

+0.71 (+0.56%)

BMY Bristol-Myers
$58.69 /

+0.64 (+1.10%)

BMY Bristol-Myers
$58.69 /

+0.64 (+1.10%)

07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
07/22/20 Morgan Stanley
Morgan Stanley sees 'encouraging news' coming in near-term for Bristol-Myers
06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
BYND Beyond Meat
$127.45 /

+0.71 (+0.56%)

07/28/20 Canaccord
Canaccord starts Beyond Meat at Hold on 'lofty valuation'
07/28/20 Canaccord
Beyond Meat initiated with a Hold at Canaccord
07/23/20 Citi
Citi does not see smooth growth trajectory for plant-based meat market
07/10/20
Fly Intel: Top five analyst initiations
SAIA Saia
$128.91 /

-0.26 (-0.20%)

07/28/20 BofA
Saia initiated with a Neutral at BofA
07/17/20 Truist
SunTrust raises price targets in select Trucking/Logistics names
06/17/20 Deutsche Bank
Saia price target raised to $133 from $112 at Deutsche Bank
04/30/20 Truist
Saia price target raised to $112 from $90 at SunTrust
PODD Insulet
$191.49 /

-1.03 (-0.54%)

07/28/20 Wells Fargo
Insulet initiated with an Overweight at Wells Fargo
07/07/20 Cowen
Insulet price target raised to $230 from $220 at Cowen
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/10/20 Piper Sandler
Tandem Diabetes the 'standout' in Piper endocrinologist survey
UBX Unity Biotechnology
$9.36 /

+0.58 (+6.61%)

07/27/20 Roth Capital
Unity Biotechnology initiated with a Buy at Roth Capital
12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
UBX Unity Biotechnology
$9.36 /

+0.58 (+6.61%)

SAIA Saia
$128.91 /

-0.26 (-0.20%)

PODD Insulet
$191.49 /

-1.03 (-0.54%)

BYND Beyond Meat
$127.45 /

+0.71 (+0.56%)

BMY Bristol-Myers
$58.69 /

+0.64 (+1.10%)

  • 13
    May
  • 01
    Aug
BYND Beyond Meat
$127.45 /

+0.71 (+0.56%)

BMY Bristol-Myers
$58.69 /

+0.64 (+1.10%)

PODD Insulet
$191.49 /

-1.03 (-0.54%)

BYND Beyond Meat
$127.45 /

+0.71 (+0.56%)

BMY Bristol-Myers
$58.69 /

+0.64 (+1.10%)

BYND Beyond Meat
$127.45 /

+0.71 (+0.56%)

BMY Bristol-Myers
$58.69 /

+0.64 (+1.10%)

Initiation
Unity Biotechnology initiated with a Buy at Roth Capital » 16:09
07/27/20
07/27
16:09
07/27/20
16:09
UBX

Unity Biotechnology

$8.85 /

+0.62 (+7.53%)

Roth Capital analyst…

Roth Capital analyst Elemer Piros initiated coverage of Unity Biotechnology with a Buy rating and $35 price target. The company is developing treatments to extend healthspan by targeting diseases of aging, Piros tells investors in a research note. Unity established early clinical evidence with its lead drug UBX0101 in osteoarthritis and a single administration of the drug improved pain and function, says the analyst.

ShowHide Related Items >><<
UBX Unity Biotechnology
$8.85 /

+0.62 (+7.53%)

UBX Unity Biotechnology
$8.85 /

+0.62 (+7.53%)

12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
UBX Unity Biotechnology
$8.85 /

+0.62 (+7.53%)

Hot Stocks
Arcus Biosciences names Bob Goeltz CFO » 16:11
07/07/20
07/07
16:11
07/07/20
16:11
RCUS

Arcus Biosciences

$25.30 /

+1.26 (+5.24%)

, UBX

Unity Biotechnology

$8.10 /

-0.77 (-8.68%)

, CTMX

CytomX Therapeutics

$8.22 /

+0.04 (+0.49%)

, GILD

Gilead

$76.40 /

-0.385 (-0.50%)

Arcus Biosciences (RCUS)…

Arcus Biosciences (RCUS) announced that Bob Goeltz will join Arcus as Chief Financial Officer on August 1, 2020. Goeltz most recently served as Chief Financial Officer and Senior Vice President of UNITY Biotechnology (UBX) and immediately before that as Chief Financial Officer of CytomX Therapeutics (CTMX). "Following the recent announcement of our 10-year collaboration with Gilead (GILD) and successful $348 million financial offering, combined with our growing portfolio of programs, I am confident Bob will play an integral role in advancing Arcus through our next phase of growth towards commercialization and beyond," said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. "Bob's experience in navigating the strategic and operational decisions necessary to transition the opportunities derived from an intense, deep and innovative R&D effort through the commercialization process to broadly benefit patients will be central to Arcus's future success. With the potential to have three molecules in registrational studies in 2021, a prolific discovery team and a uniquely enabling and nascent alliance with Gilead, Bob joins Arcus at a seminal inflection point, with the opportunity to make Arcus's vision of creating, developing and commercializing innovative and curative therapies for cancer a reality."

ShowHide Related Items >><<
UBX Unity Biotechnology
$8.10 /

-0.77 (-8.68%)

RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

GILD Gilead
$76.40 /

-0.385 (-0.50%)

CTMX CytomX Therapeutics
$8.22 /

+0.04 (+0.49%)

RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
UBX Unity Biotechnology
$8.10 /

-0.77 (-8.68%)

12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
CTMX CytomX Therapeutics
$8.22 /

+0.04 (+0.49%)

06/01/20 Jefferies
Jefferies 'underwhelmed' by CytomX presentations at ASCO, downgrades to Hold
06/01/20 Jefferies
CytomX Therapeutics downgraded to Hold from Buy at Jefferies
05/29/20 Piper Sandler
CytomX ASCO data sets point torwards Probody validation, says Piper Sandler
05/14/20 H.C. Wainwright
CytomX Therapeutics price target lowered to $12 from $16 at H.C. Wainwright
GILD Gilead
$76.40 /

-0.385 (-0.50%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
UBX Unity Biotechnology
$8.10 /

-0.77 (-8.68%)

RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

GILD Gilead
$76.40 /

-0.385 (-0.50%)

CTMX CytomX Therapeutics
$8.22 /

+0.04 (+0.49%)

  • 29
    May
RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

GILD Gilead
$76.40 /

-0.385 (-0.50%)

RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

GILD Gilead
$76.40 /

-0.385 (-0.50%)

CTMX CytomX Therapeutics
$8.22 /

+0.04 (+0.49%)

RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

GILD Gilead
$76.40 /

-0.385 (-0.50%)

Over a month ago
Hot Stocks
Unity Biotechnology names Lynne Sullivan as interim CFO » 17:01
07/06/20
07/06
17:01
07/06/20
17:01
UBX

Unity Biotechnology

$8.87 /

-0.08 (-0.89%)

, BIIB

Biogen

$269.55 /

+4.2 (+1.58%)

UNITY Biotechnology (UBX)…

UNITY Biotechnology (UBX) announced that Bob Goeltz, CFO, will leave the company at the end of July 2020 to pursue a new opportunity. Effective August 1, 2020, Lynne Sullivan, former senior vice president of Biogen (BIIB), will become UNITY's interim CFO. Ms. Sullivan worked at Biogen for over 10 years, most recently serving as senior vice president of finance with global responsibility for corporate finance, financial planning and analysis and corporate tax.

ShowHide Related Items >><<
UBX Unity Biotechnology
$8.87 /

-0.08 (-0.89%)

BIIB Biogen
$269.55 /

+4.2 (+1.58%)

UBX Unity Biotechnology
$8.87 /

-0.08 (-0.89%)

12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
BIIB Biogen
$269.55 /

+4.2 (+1.58%)

06/22/20 RBC Capital
Biogen price target lowered to $273 from $303 at RBC Capital
06/22/20 Barclays
Barclays downgrades Biogen to Equal Weight on 'mounting uncertainties'
06/22/20 Barclays
Biogen downgraded to Equal Weight from Overweight at Barclays
06/19/20 Citi
Biogen patent loss a 'major setback,' says Citi
UBX Unity Biotechnology
$8.87 /

-0.08 (-0.89%)

BIIB Biogen
$269.55 /

+4.2 (+1.58%)

BIIB Biogen
$269.55 /

+4.2 (+1.58%)

BIIB Biogen
$269.55 /

+4.2 (+1.58%)

BIIB Biogen
$269.55 /

+4.2 (+1.58%)

Hot Stocks
Unity Biotechnology provides update on lead development programs » 16:10
07/01/20
07/01
16:10
07/01/20
16:10
UBX

Unity Biotechnology

$8.44 /

-0.225 (-2.60%)

Unity Biotechnology…

Unity Biotechnology provided updates on its lead development programs. In February, Unity announced completion of enrollment of its Phase 2 study of UBX0101, a p53/MDM2 interaction inhibitor, in patients with moderate-to-severe osteoarthritis of the knee. The study is randomized, double-blind, and placebo-controlled and will evaluate three doses of UBX0101 administered via a single intra-articular injection. UNITY expects to announce 12-week results from the study in Q3. Unity announced that it has completed investigational new drug, or IND-enabling studies with UBX1325, a senolytic, small molecule inhibitor of the anti-apoptotic Bcl-2 family member, Bcl-xL. Unity expects to file an IND for a Phase 1 safety study for UBX1325 and, assuming clinical sites are able to recruit and retain investigators and study staff and screen and enroll patients during the ongoing COVID 19 pandemic, to initiate a Phase 1 study in the second half of 2020 and obtain initial results from the study in 2021. The overall clinical program is directed at multiple age-related diseases of the eye, such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration. In connection with the selection of UBX1325 as its lead molecule for the ophthalmology program, UNITY executed an amendment to an existing compound license agreement with Ascentage Pharma. The amended compound license agreement grants Unity exclusive worldwide development and commercialization rights and non-exclusive manufacturing rights outside of Greater China for UBX1325 in all non-oncology indications. Inside Greater China, Unity is obligated to commercialize UBX1325 through a joint venture with Ascentage Pharma. "The second half of 2020 will be an eventful period for UNITY, particularly for our cellular senescence programs for osteoarthritis and for age-related eye diseases," said Anirvan Ghosh, CEO of UNITY. "We expect important results from both our Phase 2 and Phase 1b studies of UBX0101 in patients with painful osteoarthritis of the knee where we see significant unmet need and the opportunity to develop a new class of therapeutic options with durable benefit. We are also excited to advance UBX1325 into clinical development in age-related eye diseases, such as diabetic macular edema and diabetic retinopathy, where senescent cell burden has been implicated and where clinicians and patients have a strong need for novel therapeutic options. UBX1325 is a Bcl-XL inhibitor and represents the second mechanism we are advancing to the clinic."

ShowHide Related Items >><<
UBX Unity Biotechnology
$8.44 /

-0.225 (-2.60%)

UBX Unity Biotechnology
$8.44 /

-0.225 (-2.60%)

12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
UBX Unity Biotechnology
$8.44 /

-0.225 (-2.60%)

Conference/Events
Goldman Sachs to hold a virtual conference » 08:47
06/11/20
06/11
08:47
06/11/20
08:47
HUM

Humana

$392.51 /

+1.51 (+0.39%)

, DTIL

Precision BioSciences

$8.30 /

-0.31 (-3.60%)

, CHNG

Change Healthcare

$11.85 /

-0.37 (-3.03%)

, ALKS

Alkermes

$16.77 /

-0.51 (-2.95%)

, ALNY

Alnylam

$129.96 /

+0.09 (+0.07%)

, HCAT

Health Catalyst

$28.79 /

+0.1 (+0.35%)

, KLDO

Kaleido Biosciences

$7.44 /

-0.155 (-2.04%)

, ZEAL

Zealand Pharma

$39.08 /

+0.48 (+1.24%)

, GOSS

Gossamer Bio

$12.38 /

-0.23 (-1.82%)

, MRNA

Moderna

$59.88 /

+1.58 (+2.71%)

, ORTX

Orchard Therapeutics

$7.99 /

+0.23 (+2.96%)

, BMY

Bristol-Myers

$60.15 /

-0.75 (-1.23%)

, ADVM

Adverum Biotechnologies

$23.85 /

+0.44 (+1.88%)

, BCYC

Bicycle Therapeutics

$17.35 /

+0.15 (+0.87%)

, ESPR

Esperion

$46.64 /

-1.01 (-2.12%)

, PHAT

Phathom Pharmaceuticals

$50.33 /

-1.45 (-2.80%)

, INSP

Inspire Medical

$85.53 /

-3.11 (-3.51%)

, UBX

Unity Biotechnology

$8.88 /

+0.32 (+3.74%)

, PHG

Philips

$46.76 /

-0.39 (-0.83%)

, ATRA

Atara Biotherapeutics

$9.91 /

-0.455 (-4.39%)

41st Annual Global…

41st Annual Global Healthcare Virtual Conference will be held on June 9-11. Webcast Link

ShowHide Related Items >><<
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

06/05/20 Goldman Sachs
Humana initiated with a Buy at Goldman Sachs
06/01/20 Stephens
Molina Healthcare price target raised to $215 from $202 at Stephens
05/21/20 Truist
SunTrust raises price targets across select Healthcare Services names
05/04/20 Mizuho
Humana price target raised to $420 from $405 at Mizuho
DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

06/10/20 KeyBanc
Inovalon displaces Change Healthcare in Priority Health deal, says KeyBanc
06/09/20 Piper Sandler
Piper Sandler says buy Change Healthcare, sell Inovalon
04/13/20 SVB Leerink
Change Healthcare initiated with an Outperform at SVB Leerink
03/26/20 Cowen
Cowen sees three healthcare IT names poised for rebound
ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

04/30/20 H.C. Wainwright
Alkermes price target lowered to $23 from $25 at H.C. Wainwright
04/29/20 Piper Sandler
Alkermes price target lowered to $21 from $22 at Piper Sandler
04/29/20 Stifel
Alkermes price target lowered to $17 from $20 at Stifel
02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

05/27/20 Piper Sandler
Piper bullish on post pandemic opportunities for Health Catalyst
05/15/20
Fly Intel: Top five analyst initiations
05/15/20 Guggenheim
Guggenheim sees Health Catalyst at attractive entry point, starts at Buy
05/15/20 Guggenheim
Health Catalyst initiated with a Buy at Guggenheim
KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Kaleido to Equal Weight amid delays for key programs
05/21/20 Morgan Stanley
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

03/10/20 Morgan Stanley
Zealand Pharma EPS estimates cut at Morgan Stanley
11/19/19 Jefferies
Zealand Pharma downgraded to Hold from Buy at Jefferies
11/15/19 Needham
Zealand Pharma price target raised to $42 from $32 at Needham
10/15/19
Fly Intel: Top five analyst upgrades
GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

05/29/20 Piper Sandler
Piper says Gossamer's GB1275 well tolerated, early activity signs 'promising'
05/20/20 SVB Leerink
Gossamer Bio price target raised to $36 from $27 at SVB Leerink
04/22/20 Piper Sandler
Gossamer Bio initiated with an Overweight at Piper Sandler
02/27/20 Barclays
Gossamer Bio initiated with an Overweight at Barclays
MRNA Moderna
$59.88 /

+1.58 (+2.71%)

06/08/20 Barclays
Moderna initiated with an Overweight at Barclays
06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
06/02/20 BofA
Moderna price target lowered to $75 from $80 at BofA
06/01/20 Goldman Sachs
Goldman keeps $105 target after Moderna COVID vaccine moves to Phase 2
ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

05/22/20 JPMorgan
Orchard Therapeutics price target lowered to $17 from $26 at JPMorgan
09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

05/29/20 Piper Sandler
Adverum Biotechnologies price target raised to $25 from $20 at Piper Sandler
05/12/20 RBC Capital
Adverum Biotechnologies initiated with an Outperform at RBC Capital
05/05/20 Truist
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
05/05/20 Truist
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
ESPR Esperion
$46.64 /

-1.01 (-2.12%)

05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
04/20/20 JMP Securities
JMP reiterates $191 price target on Esperion after Japan partnership
04/16/20 Northland
Esperion price target lowered to $42 from $60 at Northland
04/01/20
Fly Intel: Top five analyst initiations
PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

11/19/19 Evercore ISI
Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/19/19 Jefferies
Phathom Pharmaceuticals initiated with a Buy at Jefferies
INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

05/26/20 Wells Fargo
Inspire Medical price target raised to $95 from $81 at Wells Fargo
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Lake Street
Inspire Medical initiated with a Buy at Lake Street
05/06/20 Guggenheim
Inspire Medical price target raised to $90 from $80 at Guggenheim
UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
PHG Philips
$46.76 /

-0.39 (-0.83%)

04/22/20 Morgan Stanley
Philips price target lowered to EUR 45 from EUR 50 at Morgan Stanley
04/21/20 JPMorgan
Philips price target raised to EUR 36.80 from EUR 33.90 at JPMorgan
04/07/20 JPMorgan
Philips price target lowered to EUR 33.90 from EUR 43.10 at JPMorgan
03/24/20 DZ Bank
Philips upgraded to Buy from Hold at DZ Bank
ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

05/22/20 Mizuho
Atara multiple sclerosis data looks 'awesome' at first glance, says Mizuho
04/23/20 Citi
Atara Biotherapeutics upgraded to Buy on valuation at Citi
04/23/20 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.